CLINICAL USE


Ovarian and breast cancer Non-small cell lung carcinoma AIDS-related Kaposi’s sarcoma

DOSE IN NORMAL RENAL FUNCTION

100–220 mg/m2 every 3 weeks depending on local regime and duration of infusion

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :853.9
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :89–98
  • %Excreted unchanged in urine &nbsp &nbsp : 1.3–12.6

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :198–688 litres/m2

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :3–52.7

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAntidiabetics: metabolism of rosiglitazone possibly inhibited
  • Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis)

    ADMINISTRATION

    Reconstition

    –

    Route

    IV

    Rate of Administration

    3 hours depending on regime

    Comments

    Dilute to a concentration of 0.3–1.2 mg/ mL with sodium chloride 0.9% or glucose 5%Stable for 27 hours at room temperature

    OTHER INFORMATION

    Administer through a 0.22µm in line filter Use non-PVC infusion bags Hepatic metabolism and biliary clearance are the principal mechanisms for disposal. Mean values for cumulative urinary recovery of unchanged drug ranged from 1.3 to 12.6% of the dose, indicating extensive non-renal clearance.
    Tags:

    • Related News

    sotalol hydrochloride.txt

    tazocin.txt